An overview of current strategies to assess kidney safety in drug development

What is it about?

Various tools and strategies for kidney safety assessment have emerged over the past decade; however, there is currently no clear consensus on best practices for their use across different phases of drug development. Here, we provide perspective on the scope of this problem in drug development, and an overview of progress in the field of kidney safety including several informative case examples of kidney toxicity de-risking scenarios encountered in the pharmaceutical industry. The results of a survey of pharmaceutical companies conducted through the IQ Drug Safety consortium provides additional insight into recent experiences with compound attrition and different de-risking approaches across the industry.

Featured Image